Insmed Incorporated
NASDAQ:INSMBiotechnology
-$2.73 today
- Market cap
- $26.28B
- Beta
- 0.77
- P/E (TTM)
- -17.4
- EPS (TTM)
- -$5.49
Volume 1.94M
Average 3.31M
INSM Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Insmed IncorporatedNASDAQ: INSM
Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026
Income tax expense growth accelerates
Q2 FY2026 income tax expense of $1.87M rose 50.4% year over year, ahead of the +39.9% change in trailing-twelve-month income tax expense. Sequentially, it rose 27.6% from the prior quarter. Over 3 fiscal years it compounded at +53.7% a year.
Context
- Income tax expense amounted to 0.8% of revenue in FY2025, down 0.2 pp from a year earlier.
- Income tax expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +50.4% holds above the trailing-twelve-month pace of +39.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 5.03M USD
- Year-over-year change
- +35.6%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.03M | +35.6% |
| FY2024 | 2024-12-31 | 3.71M | +45.1% |
| FY2023 | 2023-12-31 | 2.56M | +84.7% |
| FY2022 | 2022-12-31 | 1.38M | +178.7% |
| FY2021 | 2021-12-31 | (1.76M) | — |
Income Tax Expense vs competitors
How INSM compares with its peers on the latest reported figures
- INSM's LTM Jun 2026 income tax expense of $6.21M is the lowest of the 4 companies compared; the peer median is $22.37M.
- Its year-over-year change of +39.9% is the 2nd highest of 3, against a peer median of +47.0%.
- Income tax expense amounts to 0.5% of revenue for INSM, versus a peer median of 8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $262.1M | -30.1% | +19.3% | 8.3% | |
| LTM Mar 2026 | $22.37M | +124.1% | +1274.1% | 20.4% | |
| LTM Jun 2026 | $10.9M | — | — | 2.4% | |
| LTM Jun 2026 | $6.21M | +39.9% | +53.7% | 0.5% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding INSM) | $22.37M | +47.0% | +646.7% | 8.3% | |
Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M |
| Cost of Revenue | 44.15M | 55.13M | 65.57M | 85.74M | 124.88M |
| Gross Profit | 144.31M | 190.23M | 239.64M | 277.97M | 481.55M |
| Gross Margin | 76.6% | 77.5% | 78.5% | 76.4% | 79.4% |
| Research & Development | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M |
| Selling, General & Admin | 234.27M | 265.78M | 344.5M | 461.12M | 701.17M |
| Operating Expenses | 519.4M | 647.55M | 949.26M | 1.16B | 1.66B |
| Depreciation & Amortization | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M |
| EBITDA | (383.65M) | (447.37M) | (660.18M) | (818.79M) | (1.17B) |
| EBITDA Margin | -203.6% | -182.3% | -216.3% | -225.1% | -193.2% |
| Operating Income | (375.09M) | (457.32M) | (709.63M) | (878.25M) | (1.18B) |
| Operating Margin | -199.0% | -186.4% | -232.5% | -241.5% | -194.0% |
| Interest Income | 174K | 11.08M | 42.13M | 53.31M | 60.66M |
| Interest Expense | 40.47M | 26.45M | 81.69M | 84.91M | 83.8M |
| Other Income / Expenses | (61.32M) | (22.83M) | (37.39M) | (31.81M) | (95.02M) |
| Income Before Tax | (436.41M) | (480.15M) | (747.01M) | (910.07M) | (1.27B) |
| Pre-Tax Margin | -231.6% | -195.7% | -244.8% | -250.2% | -209.7% |
| Income Tax Expense | (1.76M) | 1.38M | 2.56M | 3.71M | 5.03M |
| Net Income | (434.65M) | (481.53M) | (749.57M) | (913.77M) | (1.28B) |
| Net Margin | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
| EPS (Basic) | (3.88) | (3.91) | (5.34) | (5.57) | (6.41) |
| EPS (Diluted) | (3.88) | (3.91) | (5.34) | (5.57) | (6.41) |
| Weighted Avg Shares | 112.11M | 123.04M | 140.43M | 164.04M | 213.64M |
| Weighted Avg Shares (Diluted) | 112.11M | 123.04M | 140.43M | 164.04M | 213.64M |
Insmed Incorporated
NASDAQ:INSM
Intrinsic Alpha fair value
Locked
Current Price
$119.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.